USPTO serial 88021002
QUICK CONVENIENT PRECISE DISCREET
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with QUICK CONVENIENT PRECISE DISCREET?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Burlington, Ontario, CA
Burlington, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Todd A. Van Thomme
Todd A. Van Thomme Nyemaster Goode, P.C.700 Walnut StreetSuite 1600Des Moines, IA 50309Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Orally dissolvable films containing nutraceuticals, namely, biotin, folic acid, resveratrol, DHEA, NAD, curcumin; orally dissolvable films containing, vitamins, caffeine, melatonin, and herbal supplements for general health and well-being, dietary supplements for general health and well-being, nicotine and nicotine-polymer complexes; orally dissolvable films containing non-prescription pharmaceutical preparations sold over-the-counter for the relief of pain, cough, cold, flu, allergy symptoms, cardiac health, nicotine smoking cessation, anti-gas for stomach bloating, anemia, and to promote wound healing; orally dissolvable films containing prescription pharmaceutical preparations indicated for the relief of nausea, vomiting, hyperglycemia, diabetes, erectile dysfunction, anti-anxiety, anti-depressant, migraine headache pain, anemia, cardiac health, angina, hypertension, and to reverse and prevent opioid overdose; orally dissolvable films containing human vaccine and human biologic medications which function as biologic response modifiers in the human immune system for the treatment and prevention of influenza, auto-immune disease syndrome (AIDS), HIV infections, inflammatory bowel disease, Crohn's Disease, Ulcerative Colitis, rheumatoid arthritis, diabetes, insulinemia, psoriasis, herpes, HPV prevention, polio, tuberculosis, hepatitis, diphtheria, typhoid, meningitis, multiple sclerosis, lupus, Varicella viral infections (chicken pox), West Nile Virus infections, H1N1 flu infections, cancer, and age-related Macular Degeneration; none of the foregoing comprised of Cannabis sativa based ingredients | ACTIVE | — |
| 044 | Consulting in the healthcare field regarding orally dissolvable films containing nutraceuticals, namely, biotin, folic acid, resveratrol, DHEA, NAD, curcumin; consulting in the healthcare field related to orally dissolvable films containing, vitamins, caffeine, melatonin, herbal supplements for general health and well-being, dietary supplements for general health and well-being, nicotine and nicotine-polymer complexes; consulting in the healthcare field related to orally dissolvable films containing non-prescription pharmaceutical preparations sold over-the-counter for the relief of pain, cough, cold, flu, allergy symptoms, cardiac health, nicotine smoking cessation, anti-gas for stomach bloating, anemia, and to promote wound healing; consulting in the healthcare field related to orally dissolvable films containing prescription pharmaceutical preparations indicated for the relief of nausea, vomiting, hyperglycemia, diabetes, erectile dysfunction, anti-anxiety, anti-depressant, migraine headache pain, anemia, cardiac health, angina, hypertension, and to reverse and prevent opioid overdose; consulting in the healthcare field related to orally dissolvable films containing human vaccine and human biologic medications which function as biologic response modifiers in the human immune system for the treatment and prevention of influenza, auto-immune disease syndrome (AIDS), HIV infections, inflammatory bowel disease, Crohn's Disease, Ulcerative Colitis, rheumatoid arthritis, diabetes, insulinemia, psoriasis, herpes, HPV prevention, polio, tuberculosis, hepatitis, diphtheria, typhoid, meningitis, multiple sclerosis, lupus, Varicella viral infections (chicken pox), West Nile Virus infections, H1N1 flu infections, cancer, and age-related Macular Degeneration | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Rapid Dose Therapeutics Inc.
- Other trademarks owned by Rapid Dose Therapeutics Inc.
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named QUICK CONVENIENT PRECISE DISCREET
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 28, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 28, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 25, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 31, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 31, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 11, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 22, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 15, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 15, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 15, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 15, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 18, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 5, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 5, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 19, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 18, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 18, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 18, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 28, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 25, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 6, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |